Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAetna Abatacept (Orencia) Coverage Update | OpenPa…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0720

    Abatacept (Orencia)

    Customize your policy alerts

    Sign up for Aetna Policy 0720 alerts

    Get alerted when Policy 0720 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's medical necessity, precertification, prescribing specialty, and dosing/coding guidance for abatacept (Orencia) for commercial medical plans, including initial and continuation criteria for RA, JIA, PsA, graft-versus-host disease prophylaxis/treatment, and immune checkpoint inhibitor‑related toxicity.

    Policy Summary
    PayerAetna
    PolicyAbatacept (Orencia)
    Policy CodePolicy 0720
    Change TypeNo material changes
    Effective DateMar 17, 2006
    Last ReviewFeb 20, 2024
    Next Review DateAug 22, 2024
    Key ActionObtain precertification for intravenous abatacept (Orencia IV) and submit required documentation including indication, prior therapies, and TB screening.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    CommercialPolicy scope
    RequiredPrecertification
    J0129J-code
    ≥2 yrsPediatric SC age
    >20Experimental indications
    08/22/2024Next review

    Coverage Criteria for Abatacept (Orencia)

    Initial Therapy - Rheumatoid Arthritis

    Covered when ALL of the following are met for initial approval (Rheumatoid arthritis adults):

    RA initial approval - prior biologic/targeted synthetic: Member has previously received a biologic or targeted synthetic drug indicated for moderately to severely active rheumatoid arthritis (e.g., JAK inhibitors, TNF antagonists)

    Per policy: prior receipt of a biologic/targeted synthetic qualifies

    RA initial approval - biologic‑naive entry criteria

    • RA biomarker testing: Member has either a positive rheumatoid factor (RF) or positive anti‑cyclic citrullinated peptide (anti‑CCP) test; OR member has been tested for RF, anti‑CCP, and C‑reactive protein (CRP) and/or erythrocyte sedimentation rate (ESR)

      Policy requires either a positive biomarker or comprehensive testing

    • RA prior methotrexate trial or exception:
    Policy Summary
    PayerAetna
    PolicyAbatacept (Orencia)
    Policy CodePolicy 0720
    Change TypeNo material changes
    Effective DateMar 17, 2006
    Last ReviewFeb 20, 2024
    Next Review DateAug 22, 2024
    Key ActionObtain precertification for intravenous abatacept (Orencia IV) and submit required documentation including indication, prior therapies, and TB screening.
    SourceLink
    On This Page
    Coverage Criteria for Abatacept (Orencia)Coding — HCPCS, J‑codes, ICD‑10 and Dosing NotesProvider Actions, Prior Authorization and Documentation RequirementsBackground and Evidence OverviewDefinitions, Formulations and DosingPolicy Dates and Revision History
    Member has had an inadequate response to at least a 3‑month trial of methotrexate at an adequate dose (titrated to 15 mg/week) OR has an intolerance or contraindication to methotrexate
    >=3 months

    Appendix A lists clinical reasons to avoid methotrexate

    TB screening: Documented negative tuberculosis (TB) test (PPD, IGRA, or chest x‑ray) within 6 months prior to initiating abatacept for persons naïve to biologic/targeted synthetic drugswithin 6 months

    Required safety screening per policy

    Initial Therapy - Articular Juvenile Idiopathic Arthritis

    Covered when ANY of the following are met for articular juvenile idiopathic arthritis (members ≥2 years):

    JIA initial approval - prior biologic: Member (≥2 years) has previously received a biologic or targeted synthetic drug indicated for moderately to severely active articular juvenile idiopathic arthritis

    Prior biologic/targeted synthetic suffices

    JIA initial approval - csDMARD failure: Member (≥2 years) has had an inadequate response to methotrexate or another conventional synthetic DMARD (e.g., leflunomide, sulfasalazine, hydroxychloroquine) given at adequate dose and duration

    Adequate dose/duration per standard practice

    JIA initial approval - NSAID/IA steroid + risk factor: Member (≥2 years) has had an inadequate response to scheduled NSAIDs and/or intra‑articular glucocorticoids and has ONE risk factor for poor outcome (e.g., involvement of ankle, wrist, hip, sacroiliac joint, or TMJ; erosive disease; enthesitis; delay in diagnosis; elevated inflammatory markers; symmetric disease)

    Risk factors per Appendix B referenced

    JIA initial approval - high‑risk features: Member (≥2 years) has risk factors for severe or potentially refractory disease and also meets ONE high‑risk feature (e.g., high‑risk joint involvement such as cervical spine, wrist, or hip; or has high disease activity; or is judged to be at high risk for disabling joint disease)

    Appendix B risk factors referenced

    Initial Therapy - Psoriatic Arthritis

    Covered when EITHER of the following are met for psoriatic arthritis (members ≥2 years):

    PsA initial approval - prior biologic/targeted synthetic: Member (≥2 years) has previously received a biologic or targeted synthetic drug indicated for active psoriatic arthritis

    Prior biologic/targeted synthetic qualifies

    PsA initial approval - conventional therapy failure or severe disease: For members (≥2 years) without prior biologic use: EITHER (a) mild‑to‑moderate disease with inadequate response to methotrexate, leflunomide, or another conventional synthetic DMARD at adequate dose/duration OR intolerance/contraindication to those agents OR presence of enthesitis; OR (b) member has severe psoriatic arthritis

    Includes pediatric members ≥2 years; clinical activity should align with trial populations

    Initial Therapy - Prophylaxis of acute GVHD

    Covered when BOTH of the following are met for prophylaxis of acute GVHD:

    aGVHD prophylaxis - transplant donor: Member is undergoing hematopoietic stem cell transplantation (HSCT) from a matched or one allele‑mismatched unrelated donor

    Applies to members ≥2 years as per FDA indication

    aGVHD prophylaxis - concomitant regimen: Abatacept will be used in combination with a calcineurin inhibitor (e.g., cyclosporine, tacrolimus) and methotrexate as part of the prophylactic regimen

    Combination regimen consistent with trial protocols and labeling

    Initial Therapy - Chronic GVHD and Immune Checkpoint Inhibitor‑related Toxicity

    Covered when EITHER of the following are met for chronic GVHD and checkpoint inhibitor‑related toxicity:

    Chronic GVHD initial approval: Member has chronic graft‑versus‑host disease and has experienced an inadequate response to systemic corticosteroids OR has an intolerance/contraindication to systemic corticosteroids

    Alternate immunosuppressant intolerance/contraindication acceptable

    Checkpoint inhibitor‑related myocarditis initial approval: Member has immune checkpoint inhibitor‑related myocarditis and has experienced an inadequate response to systemic corticosteroids OR has an intolerance/contraindication to systemic corticosteroids

    Indication limited to myocarditis per policy language

    Continuation of Therapy

    Covered for continuation when ALL of the following are met:

    Continuation - RA: Member using abatacept for moderately to severely active rheumatoid arthritis (including new members) who achieves or maintains a positive clinical response as evidenced by at least 20% improvement from baseline in tender joint count, swollen joint count, pain, or disability>=20% improvement

    Document objective measures of response

    Continuation - JIA: Member (≥2 years) using abatacept for articular juvenile idiopathic arthritis (including new members) who achieves or maintains low disease activity or improvement in ANY of: number of joints with active arthritis, number of joints with limitation of movement, or functional ability

    Improvement in any one domain supports continuation

    Continuation - PsA: Member (≥2 years) using abatacept for psoriatic arthritis (including new members) who achieves or maintains low disease activity or improvement in ANY of: swollen joints, tender joints, dactylitis, enthesitis, or skin/nail involvement

    Documented improvement in any listed sign/symptom supports continuation

    Initial coverage criteria

    Covered when ALL of the following are met

    FDA‑approved indication: The requested use is for an FDA‑approved indication (adult RA; polyarticular JIA ≥2 years; active PsA ≥2 years; or prophylaxis of aGVHD in HSCT recipients)

    See FDA‑approved indications

    Clinical justification and prior therapy: Documentation of disease activity and prior therapy appropriate to the indication is provided (e.g., inadequate response, intolerance, or contraindication to conventional DMARDs and/or prior biologics/TNF antagonists where applicable)

    Trial populations often had prior DMARD failure; document prior treatments

    Safety screening and contraindications: Evidence of screening for latent tuberculosis and viral hepatitis prior to initiation and documentation that abatacept will not be given concomitantly with TNF antagonists or other disallowed biologic RA therapies

    TB screening within 6 months for biologic‑naive patients; avoid concomitant TNF antagonists per label

    Pediatric coverage

    Pediatric dosing and coverage considerations

    Pediatric age and dosing guidance: Subcutaneous abatacept is approved for juvenile idiopathic arthritis and psoriatic arthritis for patients 2 years of age and older. Intravenous pediatric dosing (6–17 years): 10 mg/kg for patients weighing <75 kg; patients ≥75 kg follow adult dosing (maximum 1,000 mg). Infusion schedule: initial, weeks 2 and 4 after first infusion, then every 4 weeks thereafter.age >=2 years; weight‑based dosing as specified

    SC approval age and IV pediatric dosing per labeling and trials

    Pediatric prior therapy relevance: Clinical pediatric trials generally enrolled patients who had failed one or more DMARDs; documentation of prior DMARD failure may be relevant to coverage determinations despite labeling allowing use without prior DMARDs

    Trial populations focused on DMARD‑refractory patients

    Covered Indications and Required Documentation

    Covered when ALL of the following are met (based on evidence and FDA labeling in these sections):

    Coverage - juvenile idiopathic arthritis: Patient has a diagnosis of polyarticular juvenile idiopathic arthritis for which abatacept is FDA‑approved; dosing will follow age‑ and weight‑based recommendations; clinical justification provided (e.g., inadequate response to prior DMARDs or biologics as applicable)age/weight per labeling

    Pediatric IV dosing: 10 mg/kg for 6–17 years <75 kg; >=75 kg use adult regimen (max 1000 mg)

    Coverage - psoriatic arthritis: Patient has active psoriatic arthritis consistent with trial populations and documentation of prior DMARD therapy where applicable; pediatric SC formulation approval (>=2 years) noted and dosing per labeling will be followedclinical activity documented

    Responses observed regardless of prior TNF inhibitor use in trials

    Coverage - prophylaxis of aGVHD: Patient undergoing HSCT from an unrelated donor (matched or one allele‑mismatched) with planned concomitant immunosuppression (calcineurin inhibitor + methotrexate) as per trials; dosing per GVHD trials (e.g., IV 10 mg/kg up to 1,000 mg on Day ‑1 and Days 5, 14, 28) is specifiedtransplant donor type and regimen documented

    Evidence from trials demonstrated improved OS and aGVHD‑free survival at 6 months

    Evidence summary by indication

    Summary of clinical evidence and implied coverage considerations by indication

    Type 1 diabetes (recent onset): Randomized double‑blind trial showed abatacept slowed decline in C‑peptide over 2 years with an estimated delay in C‑peptide reduction, but effect attenuated after 6 months and longer‑term implications remain uncertain

    Orban et al. 2011; n=112 randomized (2:1)

    Giant cell arteritis: Small randomized double‑blind trial (n=49) demonstrated reduced relapse rate and longer median remission with abatacept versus placebo when added to prednisone, but sample size was small and follow‑up limited

    Langford et al. 2017a

    Dermatomyositis/Polymyositis: Pilot randomized/delayed‑start trial in refractory adult dermatomyositis/polymyositis showed preliminary signals of benefit in a small cohort (n≈20) that require phase‑III confirmation

    Tjamlund et al. 2018

    Granulomatosis with polyangiitis: Open‑label study (n=20) reported improvement/remission but was uncontrolled and preliminary; further validation needed

    Langford et al. 2014

    RA‑associated interstitial lung disease: Observational data and systematic reviews report improvement or stabilization of ILD in many patients treated with abatacept versus TNF inhibitors in cohort data, but randomized trials are lacking

    Vicente‑Rabaneda et al. 2021; observational evidence

    Other preliminary reports: Evidence for indications such as juvenile dermatomyositis, calcinosis, FSGS (B7‑1 positive), localized scleroderma, and other rare conditions is limited to case reports/series or small uncontrolled studies and is insufficient for routine coverage

    Multiple small series and case reports cited

    Coverage stance for off-label/other indications

    Coverage for abatacept in these indications is generally investigational or supported only in limited circumstances; the document presents condition‑specific evidence summaries rather than formal coverage criteria.

    FSGS/Nephrotic syndromes (TRNS): Abatacept has been used in case reports/series for primary and recurrent FSGS and treatment‑resistant nephrotic syndrome; evidence is mixed and may depend on podocyte B7‑1 (CD80) staining status; randomized trials are planned and biomarker‑guided use may be required in study contextsbiopsy/biomarker evidence may be required in trials

    Evidence uncertain; trial planned (Trachtman et al.)

    Localized scleroderma / Morphea: Small uncontrolled series in juvenile and adult localized scleroderma report clinical improvement with abatacept in treatment‑resistant cases; evidence quality is low and routine coverage is investigationalprior failure of standard therapies and documented disease activity scores (LoSCAT, MRSS)

    Small series and high risk of bias

    Lupus nephritis: Secondary analyses suggest that interpretation of abatacept trials in lupus nephritis depends on the definition of complete response; signals exist but further study is needed before routine coveragetrial‑defined CR criteria

    Wofsy et al. analysis

    Other Indications — evidence summaries

    Evidence summaries for other indications of abatacept:

    Rheumatoid pleural effusion: Single‑case report described resolution of refractory rheumatoid pleural effusion after abatacept; preliminary evidence onlycase report only

    Fujita et al. 2018

    Rheumatoid vasculitis: Isolated case report described improvement in cutaneous rheumatoid vasculitis after abatacept when other therapies failed; evidence hypothesis‑generatingcase report only

    Al Attar and Shaver 2018

    Scleritis: Retrospective series (n=14) including abatacept among other biologics reported improved inflammatory grading and fewer relapses; small heterogeneous cohort and not conclusivesmall retrospective cohort

    Fabiani et al. 2020

    Spondyloarthritis/axial disease: Systematic review and small studies do not support meaningful efficacy of abatacept in axial spondyloarthropathies; evidence limited or negativenegative/limited evidence

    De La Mata et al. 2011

    Takayasu arteritis: Randomized double‑blind trial showed no benefit of abatacept versus placebo for prolonging remission in Takayasu arteritis; abatacept did not improve relapse‑free survivalRCT negative

    Langford et al. 2017b

    Use of abatacept concomitantly with any other biologic or targeted synthetic drug for the same indication is considered experimental and investigational because the effectiveness of combined biologic/targeted synthetic therapy has not been established.

    The policy lists specific ICD-10 codes not covered for indications listed in the CPB (not an all-inclusive list). Claims using those diagnoses (for example, G35 for multiple sclerosis, the K50.* and K51.* series for Crohn's disease and ulcerative colitis, and codes for psoriasis and morphea) may trigger denial if submitted as the indication for abatacept.

    Concurrent administration of abatacept with tumor necrosis factor (TNF) antagonists or other biologic rheumatoid arthritis therapies (for example, anakinra) is contraindicated per labeling and is associated with higher rates of infections; such combination use is not permitted.

    Randomized induction and maintenance trials in inflammatory bowel disease demonstrated no consistent benefit for abatacept; the studies showed that abatacept is not efficacious for moderate-to-severe Crohn's disease or ulcerative colitis and coverage for these indications is not supported.

    Multiple UpToDate reviews and guideline summaries for several conditions do not list abatacept as a therapeutic option (for example, localized scleroderma/morphea and psoriasis), indicating that abatacept is not recognized as a standard treatment for these conditions in current reviews.

    In a randomized, double-blind, multicenter trial for Takayasu arteritis, abatacept did not increase relapse-free survival versus placebo and did not prolong median remission; the trial therefore did not demonstrate efficacy for TAK.

    These document segments include appendices, references, and policy administrative language but do not list any additional explicit coverage exclusions beyond those described elsewhere in the CPB.

    The Clinical Policy Bulletin provides a partial, general description of plan or program benefits and is not a contract; statements in the CPB (including the abbreviated coverage descriptions in this bulletin) are for administrative guidance and do not by themselves create contractual rights or obligations.

    For members who are new to targeted immune modulators, Orencia IV (intravenous abatacept) is considered medically necessary only when a documented contraindication, intolerance, or ineffective response to specified lower-cost alternative targeted immune modulators is present; otherwise IV brand selection restrictions may result in noncoverage.

    Combination therapy of abatacept with a TNF antagonist is considered not medically necessary because trials showed increased rates of infections and serious infections without improved effectiveness.

    The randomized trial program for Crohn's disease and ulcerative colitis found no consistent clinical benefit for abatacept; as a result, abatacept is considered not medically necessary for moderate-to-severe Crohn's disease and ulcerative colitis.

    The policy reiterates that evidence does not support abatacept use in Crohn's disease or ulcerative colitis and that coverage for these indications is not supported by randomized trial data.

    There is insufficient evidence to support abatacept for certain autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus; these indications are unsupported outside of clinical trials.

    Available data for axial spondyloarthropathies come from small series and limited studies that did not show meaningful benefit; abatacept for axial forms of spondyloarthritis is therefore generally not supported by current evidence.

    This portion of the document (appendix material and references) does not contain explicit new 'not medically necessary' criteria; it mainly provides supporting appendices and bibliographic information.

    Coding — HCPCS, J‑codes, ICD‑10 and Dosing Notes

    Covered CPT/HCPCS and related codesmixedCovered
    71045-71048Radiologic examination, chest
    85651Sedimentation rate, erythrocyte; non-automated
    85652Sedimentation rate, erythrocyte; automated
    86140C-reactive protein
    86141C-reactive protein; high sensitivity (hsCRP)
    86200Cyclic citrullinated peptide (CCP), antibody
    86430Rheumatoid factor; qualitative
    86431Rheumatoid factor; quantitative
    86480Tuberculosis test, cell mediated immunity antigen response measurement; gamma interferon
    86481Tuberculosis test, cell mediated immunity antigen response measurement; enumeration of gamma interferon-producing T cells in cell suspension
    1–10 of 14
    1/2
    Other HCPCS codes referencedHCPCS
    J0135Injection, adalimumab, 20 mg
    J0717Injection, certolizumab pegol, 1 mg
    J1745Injection, infliximab, 10 mg
    Q5103Injection, infliximab-dyyb (Inflectra), 10 mg
    Q5104Injection, infliximab-abda (Renflexis), 10 mg
    Q5109Injection, infliximab-qbtx (Ixifi), 10 mg
    J9312Injection, rituximab, 10 mg
    Q5115Injection, rituximab-abbs (Truxima), 10 mg
    HCPCS / J-codes (group 1)HCPCS
    J1020Injection, methylprednisolone acetate, 20 mg
    J1030Injection, methylprednisolone acetate, 40 mg
    J1040Injection, methylprednisolone acetate, 80 mg
    J1094Injection, dexamethasone acetate, 1 mg
    J1100Injection, dexamethasone sodium phosphate, 1 mg
    J1438Injection, etanercept, 25 mg
    J1600Injection, gold sodium thiomalate, up to 50 mg
    J1700Injection, hydrocortisone acetate, up to 25 mg
    J1710Injection, hydrocortisone sodium phosphate, up to 50 mg
    J1720Injection, hydrocortisone sodium succinate, up to 100 mg
    1–10 of 22
    1/3
    HCPCS / J- and Q-codes (group 2)HCPCS
    J7500Azathioprine, oral, 50 mg
    J7501Azathioprine, parenteral, 100 mg
    J7509Methylprednisolone oral, per 4 mg
    J7510Prednisolone oral, per 5 mg
    J7512Prednisone, immediate release or delayed release, oral, 1 mg
    J8540Dexamethasone, oral, 0.25 mg
    J8610Methotrexate, oral, 2.5 mg
    J9250Methotrexate sodium, 5 mg
    J9255Injection, methotrexate (accord) not therapeutically equivalent to J9250 or J9260, 50 mg
    J9260Methotrexate sodium, 50 mg
    1–10 of 18
    1/2
    Biosimilar Q-codesHCPCS
    Q5131Injection, adalimumab-aacf (Idacio), biosimilar, 20 mg
    Q5132Injection, adalimumab-afzb (Abrilada), biosimilar, 10 mg
    Covered ICD-10 codes if selection criteria metICD-10Covered
    D89.811Chronic graft-versus-host disease
    D89.812Acute on chronic graft-versus-host disease
    I40.0 - I40.9Acute myocarditis [immune checkpoint inhibitor-related cardiac toxicity]
    I41Myocarditis in diseases classified elsewhere [immune checkpoint inhibitor-related cardiac toxicity]
    L40.50 - L40.59Arthropathic psoriasis [age 2 and older]
    M05.00 - M05.09; M05.20 - M06.39; M06.80 - M06.9Rheumatoid arthritis [age 18 and older]
    M08.00 - M08.9Juvenile arthritis
    ICD-10 codes not covered for indications listed in the CPB (not all-inclusive)ICD-10Not Covered
    D83.0 - D83.9Common variable immunodeficiency
    D89.810Acute graft-versus-host disease
    D89.813Graft-versus-host disease, unspecified
    E10.10 - E10.9Type 1 diabetes mellitus
    G35Multiple sclerosis
    J84.0 - J84.9Other interstitial pulmonary diseases
    H15.091 - H15.099Other scleritis [non-infectious refractory scleritis]
    K50.00 - K50.919Crohn's disease (regional enteritis)
    K51.00 - K51.919Ulcerative colitis
    K68.9Other disorders of retroperitoneum [encapsulated peritoneal sclerosis]
    1–10 of 33
    1/4
    Coding notesmixed
    NDC or HCPCS not specified in this sectionNo specific billing codes listed in this document portion.
    Weight-based dosing thresholds — IV and SC dosing by weight and pediatric bands
    Adult IV weight bands<60 kg = 500 mg; 60–100 kg = 750 mg; >100 kg = 1,000 mg (IV schedule: 0, 2, 4 weeks then every 4 weeks)
    Pediatric IV dosing (6–17 yrs)<75 kg = 10 mg/kg per infusion; >=75 kg = follow adult IV regimen (max 1,000 mg); schedule: initial, 2 and 4 weeks, then every 4 weeks
    Pediatric SC weight bands (2+ yrs)10 to <25 kg = 50 mg weekly; 25 to <50 kg = 87.5 mg weekly; >50 kg = 125 mg weekly (SC, no IV loading dose)
    aGVHD IV dosing (>=6 yrs)10 mg/kg IV (max 1,000 mg) on Day -1, and Days 5, 14, and 28 (60-minute infusion)
    aGVHD IV dosing (2 to <6 yrs)Day -1: 15 mg/kg IV; Days 5, 14, 28: 12 mg/kg IV (60-minute infusions); max dose guidance per labeling
    ACR Pedi 30 response — pediatric response assessment
    ACR Pedi 30 definition≥30% improvement in at least 3 of 6 ACR Pedi variables with no more than 1 variable worsening by ≥30%
    Use in trialsPrimary pediatric JIA efficacy endpoint in IV study; used to assess response at 4 months in pivotal trial
    Flare definition (trial)Flare = ≥30% worsening in ≥3 of 6 ACR Pedi variables plus at least 2 active joints and no more than 1 indicator improving by 30%
    Pediatric IV dose — 10 mg/kg details and adult regimen for ≥75 kg
    Pediatric IV standard dose (6–17 yrs, <75 kg)10 mg/kg per infusion (30-minute infusion); initial, at 2 and 4 weeks, then every 4 weeks
    Pediatric >=75 kgFollow adult IV dosing regimen (weight bands 500–1,000 mg) with maximum dose 1,000 mg
    Adult IV schedule referencedAdministered at 0, 2, and 4 weeks, then every 4 weeks as a 30-minute infusion
    Pediatric SC approval age — subcutaneous formulation age indication
    SC formulation pediatric approval ageSubcutaneous Orencia approved for children 2 years of age and older for pJIA and pediatric PsA (per 2023 expansion)
    SC dosing initiationSC dosing for pediatrics is weight-based per Table 2 and is initiated without an IV loading dose
    IV not approved for pediatric PsAIV administration is not approved for pediatric psoriatic arthritis (SC only for PsA pediatrics)

    Provider Actions, Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Precertification and prior authorization are required for intravenous abatacept (Orencia IV). For precertification of Orencia IV, contact Aetna at (866) 752-7021 or fax (888) 267-3277 and submit the Statement of Medical Necessity (SMN) / prior authorization documentation per plan procedures. Clinical Policy Bulletins (CPBs) and specific plan procedures govern coverage determinations — CPBs assist in administering benefits but do not guarantee coverage or substitute for clinical judgment.

    • Precertification contact: (866) 752-7021; fax: (888) 267-3277.
    • Submit Statement of Medical Necessity (SMN) or equivalent prior authorization form as required by plan.
    Documentation Required

    Indication, Dosing and Transplant Context

    Document the requested FDA-approved indication or recognized compendial use, including specific indication, dosing, and transplant context (when applicable). For transplant-related indications (eg, aGVHD prophylaxis), include transplant details: donor type, transplant date, conditioning regimen, and concurrent prophylactic immunosuppression.

    • Indication (FDA-approved or compendial) and intended dosing regimen.
    • For HSCT: donor type (matched/1-allele mismatch), transplant date, and concurrent CNI/MTX use.
    Documentation Required

    Indication, Age/Weight and Prior Therapy

    Provide the member’s age and weight (for pediatric dosing), prior therapy history, and specific details of prior treatment failures, contraindications or intolerance to alternatives. When required by brand-step rules, document trials of specified alternative targeted immune modulators and duration of each trial (eg, one-month trials of specified lower-cost alternatives for certain RA and PsA indications).

    • Age and weight (include for pediatric dosing calculations).
    • List prior DMARDs, targeted therapies, and duration of trials with outcomes (ineffective, intolerance, or contraindication).
    • When brand-step applies, document trials of listed less-costly targeted immune modulators and reasons for failure or exception.
    Prior Authorization

    Prior Authorization for Off‑Label / Refractory and Small‑Study Indications

    Prior authorization is expected for off‑label, refractory, or small-study indications. Requests for indications supported only by small case series, open-label studies, or single-arm reports (eg, granulomatosis with polyangiitis, RA‑ILD, localized scleroderma, nephrotic syndrome/TRNS, other rare uses) must include a clinical justification and supporting evidence (published studies, trial data, or rationale). Limited or low-quality evidence may lead to denial.

    • Attach relevant publications, study summaries, or trial protocols supporting the request.
    • Explain why standard therapies are inappropriate or have failed.
    • Note that small-study evidence (case series, open‑label, n<=20 etc.) may be insufficient and may result in denial.
    Documentation Required

    Documentation Required for Off‑Label Use

    When requesting coverage for off‑label abatacept use, include detailed clinical documentation: diagnosis with ICD‑10 code, prior treatments and durations, objective measures of disease activity, prior randomized trial evidence if available, and the clinical rationale for using abatacept. Cite supporting references and any relevant trial data.

    • Diagnosis and relevant ICD‑10 codes (note: some ICD‑10 codes are listed as not covered for CPB indications).
    • Prior treatment history with dates and outcomes; objective labs/imaging and disease activity scores where applicable.
    • Relevant randomized trial data or structured evidence summaries, and bibliographic references.
    Billing Rule

    ICD‑10 and Coverage

    ICD‑10 diagnoses: verify that the submitted diagnosis is covered under this CPB. Some ICD‑10 codes are explicitly listed as not covered for indications in this CPB (not all‑inclusive); include alternate supporting documentation if the requested use is a compendial or FDA‑approved indication.

    • Check coding table for covered vs not‑covered ICD‑10 codes before submission.
    • If diagnosis appears in the CPB not‑covered list, provide justification or alternative diagnosis supported by documentation.
    Step Therapy

    Prior DMARD Trial Documentation and Step‑Therapy Context

    Provide trial evidence and a complete treatment history for the condition being treated. For FDA‑approved indications where labeling or clinical guidelines recommend prior DMARD trials, document prior DMARD (eg, methotrexate, leflunomide) use and reasons to avoid them per Appendix A (eg, pregnancy, liver disease, drug interaction, intolerance).

    • Document prior DMARD trials, durations, and outcomes (ineffective, intolerant, contraindicated).
    • If bypassing step therapy, document a clinical reason from Appendix A to avoid methotrexate or leflunomide.
    Note

    Clinical Policy Bulletin and Plan Procedures

    Aetna uses Clinical Policy Bulletins (CPBs) and plan procedures to determine coverage. CPBs provide clinical guidance and administration rules but do not guarantee coverage. Participating providers remain responsible for clinical management.

    • Refer to the applicable CPB and plan-specific procedures for coverage rules.
    • CPBs are administrative aids and do not replace clinical judgement.
    Denial Risk

    Authorization Decision Notes and Denial Risk

    Be aware that there are no single, specific authorization triggers contained in this section beyond the general requirements above; authorization determinations are made based on whether submitted documentation meets the CPB criteria and plan procedures. If documentation is incomplete or evidence is limited, the request may be denied.

    • Incomplete prior‑therapy documentation, missing age/weight, or absent transplant details may delay or result in denial.
    • Limited evidence for the requested indication increases risk of denial.

    Background and Evidence Overview

    Abatacept (Orencia) is a selective co‑stimulation modulator (CTLA‑4–Ig fusion protein) available as both an intravenous infusion and subcutaneous injection and is indicated for conditions including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, and prophylaxis of acute graft‑versus‑host disease in HSCT recipients. Dosing varies by formulation, indication, age, and weight.

    Definitions, Formulations and Dosing

    Orencia IV and SC preparations — formulations and presentations
    IV presentation250 mg lyophilized powder in single‑dose vial for reconstitution (used to prepare IV infusion)
    SC prefilled syringes50 mg/0.4 mL; 87.5 mg/0.7 mL; 125 mg/mL single‑dose prefilled syringes
    SC ClickJect autoinjector125 mg/mL solution in a single‑dose prefilled ClickJect autoinjector
    Dosing summary — dosing varies by indication, age, weight with IV weight-based regimens and SC dosing
    Route and regimen vary by indicationDosing and route (IV vs SC) differ by indication, age, and weight; IV regimens are weight‑based and SC doses are fixed or weight‑banded in pediatrics
    Adult IV regimenIV: weight‑based dosing at 0, 2, 4 weeks then every 4 weeks (30‑minute infusion)
    Adult SC regimenSC: 125 mg once weekly (may use optional IV loading prior to first SC dose)
    Pediatric dosing summaryIV for pJIA (≥6 yrs): 10 mg/kg if <75 kg; SC for pJIA/PsA (≥2 yrs): weight‑banded weekly dosing per Table 2
    Abatacept (Orencia) — mechanism brief definition
    Mechanism (brief)Selective co‑stimulation modulator (CTLA‑4‑Ig) that inhibits T‑cell activation by binding CD80/CD86 and blocking CD28 interaction
    Therapeutic roleDownregulates T‑cell activation implicated in RA, pJIA and PsA pathogenesis
    Molecular formatFusion protein incorporating CTLA‑4 extracellular domain linked to an IgG1 Fc region
    FDA-approved indications — listed FDA-approved uses
    Rheumatoid arthritis (adults)Moderately to severely active rheumatoid arthritis
    Polyarticular juvenile idiopathic arthritispJIA in patients 2 years of age or older
    Psoriatic arthritisActive psoriatic arthritis in patients 2 years of age or older
    aGVHD prophylaxisProphylaxis of acute graft‑versus‑host disease in HSCT (with CNI + methotrexate) for patients ≥2 years
    ACR Pedi 30 — definition for pediatric response metric
    ACR Pedi 30 metric≥30% improvement in ≥3 of 6 ACR Pedi variables with ≤1 variable worsening by ≥30%
    Used as primary pediatric endpointEndpoint used to assess efficacy in pediatric JIA IV trial; responses reported at 4 months and maintained in extensions
    Flare as converse metricTrial defined flare as ≥30% worsening in ≥3 of 6 variables plus ≥2 active joints
    aGVHD — definition/brief description
    aGVHD definition (brief)Acute graft‑versus‑host disease: donor immune cells attack recipient tissues after HSCT; graded I–IV with moderate‑severe often defined as grade II–IV
    Clinical contextProphylaxis studied in HSCT recipients in combination with calcineurin inhibitor and methotrexate
    Outcomes referencedTrials measured aGVHD‑free survival and overall survival at 6 months
    Mechanism of action — CTLA‑4 Ig fusion protein binding CD80/CD86 summary
    CTLA‑4 Ig bindingSoluble fusion protein (CTLA‑4 extracellular domain fused to IgG1 Fc) that binds CD80/CD86, preventing CD28 co‑stimulation of T cells
    Effect on T cellsBlocks co‑stimulatory signal necessary for full T‑cell activation, reducing pathologic immune responses
    Relation to disease mechanismTargets activated T lymphocytes implicated in RA, pJIA, and PsA synovial pathology
    CTLA4‑Ig / co‑stimulatory antagonist — definition entry
    DefinitionCo‑stimulatory antagonist (CTLA4‑Ig): biologic agent that blocks CD80/CD86 interaction with CD28 on T cells to inhibit T‑cell activation
    Class exampleAbatacept is a CTLA‑4‑Ig fusion protein functioning as a co‑stimulatory antagonist
    Clinical implicationInhibits T‑cell co‑stimulation to modulate autoimmune inflammation
    Abatacept (CTLA-4Ig) — molecular composition definition
    Molecular compositionFusion protein composed of the extracellular domain of CTLA‑4 joined to the Fc region of human IgG1
    Functional consequenceLimits T‑cell activation by binding APC CD80/CD86 and blocking CD28 engagement
    Synoptic termAlso described as CTLA‑4‑Ig or CTLA4‑Ig (abatacept) in literature and labeling
    Risk factors (appendix heading) — reference to Appendix B
    Appendix referenceSee Appendix B: Risk Factors for Articular Juvenile Idiopathic Arthritis
    PurposeAppendix B lists clinical risk factors referenced in pediatric JIA coverage criteria
    LocationAppendix B included in policy appendices section
    Clinical Policy Bulletin — definition/disclaimer of CPB role
    DefinitionClinical Policy Bulletin (CPB): Aetna document developed to assist in administering plan benefits; not an offer of coverage or medical advice
    FunctionProvides policy criteria, dosing, coding and evidence summaries to guide coverage determinations
    CaveatDoes not guarantee coverage; specific plan provisions and prior authorization requirements apply

    Policy Dates and Revision History

    Precertification (prior authorization) is required for intravenous abatacept (Orencia IV). Providers should contact Aetna's precertification resources and submit clinical documentation, including the Statement of Medical Necessity and supporting records, as applicable.